ARCHIVES

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

This article is from The Cancer Letter archive.

Vol. 28 No. 8 | August 26, 2005

Download PDF Visit The Full Archive

Related Articles

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

March 28, 2014

House Subcommittee Passes Bush Request for NIH, NCI Budgets.

June 9, 2006

DCE Board Approve Concepts For Contract Recompetitions

November 23, 1984

In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro

September 20, 1991

Cooperative Groups: Group Affiliates, Statistical Offices At Top Of NCI’s Most Needy Cases List

November 13, 1998

Hairy Cell Leukemia Patients Have CRs In Phase I Trial

September 28, 2001